ArticleJournal of Cancer2013
Identification of caveolin-1 as a potential causative factor in the generation of trastuzumab resistance in breast cancer cells.
Article in Journal of Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- Antibody-drug conjugates in gastric cancer: clinical advances and resistance mechanisms.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Review
- Caveolin-1: an ambiguous entity in breast cancer.Molecular cancer · 2025Review
- [Molecular pharmaceutics · 2024Article
- PET and Optical Imaging of Caveolin-1 in Gastric Tumors.ACS omega · 2023Article
- Caveolin-1 promotes glioma progression and maintains its mitochondrial inhibition resistance.Discover oncology · 2023Article
- Metformin-Induced Receptor Turnover Alters Antibody Accumulation in HER-Expressing Tumors.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Antitumor Activity of Taxol Engross Taxol-Caveolin-1 Interaction via Lipid Raft Structure-"Caveolae".Applied biochemistry and biotechnology · 2023Article
- Optimize the combination regimen of Trastuzumab and Nab-paclitaxel in HER2-positive tumors via modulating Caveolin-1 expression by lovastatin.Asian journal of pharmaceutical sciences · 2022Article
- Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer.Nature communications · 2022Article
- Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma.Cancers · 2021Article
- The role of caveolin-1 in the biofate and efficacy of anti-tumor drugs and their nano-drug delivery systems.Acta pharmaceutica Sinica. B · 2021Review
- Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells.Drug design, development and therapy · 2021Article
- A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers.Cancer biology & therapy · 2020Article
- Caveolae as Potential Hijackable Gates in Cell Communication.Frontiers in cell and developmental biology · 2020Review
- Flow cytometry-based assessment of direct-targeting anti-cancer antibody immune effector functions.Methods in enzymology · 2020Article
- Strategic Trastuzumab Mediated Crosslinking Driving Concomitant HER2 and HER3 Endocytosis and Degradation in Breast Cancer.Journal of Cancer · 2020Article
- Caveolin-1: a multifaceted driver of breast cancer progression and its application in clinical treatment.OncoTargets and therapy · 2019Review
- Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy.Nature communications · 2018Article
- Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells.Scientific reports · 2018Article
- Targeting Glioblastoma Cells Expressing CD44 with Liposomes Encapsulating Doxorubicin and Displaying Chlorotoxin-IgG Fc Fusion Protein.International journal of molecular sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The oncogenic tyrosine kinase receptor ErbB2 is a prognostic factor and target for breast cancer therapeutics. In contrast with the other ErbB receptors, ErbB2 is hardly internalized by ligand induced mechanisms, indicating a prevalent surface expression. Elevated levels of ErbB2 in tumor cells are associated with its defective endocytosis and down regulation. Here we show that caveolin-1 expression in breast cancer derived SKBR-3 cells (SKBR-3/Cav-1) facilitates ligand induced ErbB2 endocytosis using an artificial peptide ligand EC-eGFP. Similarly, stimulation with humanized anti ErbB2 antibody Trastuzumab (Herceptin) was found to be internalized and co-localized with caveolin-1 in SKBR-3/Cav-1 cells. Internalized EC-eGFP and Trastuzumab in SKBR-3/Cav-1 cells were then delivered via caveolae to the caveolin-1 containing early endosomes. Consequently, attenuated Fc receptor mediated ADCC functions were observed when exposed to Trastuzumab and EC-Fc (EC-1 peptide conjugated to Fc part of human IgG). On the other hand, this caveolae dependent endocytic synergy was not observed in parental SKBR-3 cells. Therefore, caveolin-1 expression in breast cancer cells could be a predictive factor to estimate how cancer cells are likely to respond to Trastuzumab treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.